ICMR transfers three indigenous biomedical technologies to advance cancer and infectious disease solutions

Key Highlights:

• ICMR transferred three indigenous biomedical technologies for cancer and infectious disease solutions.
• Technologies include SHetA2 for cervical cancer and two next-generation vaccine candidates for enteric bacterial infections.
• SHetA2 was licensed to Emcure Pharmaceuticals Ltd., while the vaccine technologies were licensed to Biological E Ltd.
• The transfers were facilitated under Medical Innovations Patent Mitra, an ICMR initiative.
• This aims to accelerate the translation of publicly funded research into affordable healthcare solutions and strengthen India's biomedical innovation ecosystem.

Detailed Insights:

• SHetA2 is a novel anti-HPV therapeutic candidate for treating Cervical Intraepithelial Neoplasia (CIN).
• It was developed through a collaboration between ICMR-NICPR and the University of Oklahoma, USA.
• SHetA2 is a first-in-class targeted therapeutic that selectively eliminates HPV-induced precancerous and cervical cancer cells.
• The two vaccine technologies were developed at ICMR-NIRBI and target Salmonella typhi (typhoid) and Salmonella typhi/paratyphi and Shigella infections.
• These technologies aim to provide broader protection against major enteric bacterial pathogens.
• ICMR emphasizes translating publicly funded research into products that improve health outcomes and achieve self-reliance in healthcare innovation.
• MedTech Mitra is another ICMR initiative supporting regulatory guidance, clinical evaluation, and market access for indigenous medical technologies.

Key Concepts Involved:

• Medical Innovations Patent Mitra: An ICMR initiative providing structured support for patent filing, technology transfer, and licensing of innovations.
• Cervical Intraepithelial Neoplasia (CIN): A precancerous condition caused by HPV that involves abnormal cell growth on the surface of the cervix.
• HPV (Human Papillomavirus): A common group of viruses, certain types of which can cause CIN and cervical cancer.
• MedTech Mitra: An ICMR initiative facilitating regulatory guidance, clinical evaluation, and market access for indigenous medical technologies.